Dalian BIO-CHEM Company Limited

SHSE:603360 Lagerbericht

Marktkapitalisierung: CN¥10.3b

Dalian BIO-CHEM Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Dalian BIO-CHEM.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Chemicals Gewinnwachstum38.3%
Wachstumsrate der Einnahmenn/a
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

None

Zuletzt aktualisiertn/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Shareholders Are Optimistic That Dalian BIO-CHEM (SHSE:603360) Will Multiply In Value

Oct 29
Shareholders Are Optimistic That Dalian BIO-CHEM (SHSE:603360) Will Multiply In Value

Market Might Still Lack Some Conviction On Dalian BIO-CHEM Company Limited (SHSE:603360) Even After 29% Share Price Boost

Oct 01
Market Might Still Lack Some Conviction On Dalian BIO-CHEM Company Limited (SHSE:603360) Even After 29% Share Price Boost

Here's Why Dalian BIO-CHEM (SHSE:603360) Can Manage Its Debt Responsibly

Sep 26
Here's Why Dalian BIO-CHEM (SHSE:603360) Can Manage Its Debt Responsibly

These 4 Measures Indicate That Dalian BIO-CHEM (SHSE:603360) Is Using Debt Reasonably Well

Jun 12
These 4 Measures Indicate That Dalian BIO-CHEM (SHSE:603360) Is Using Debt Reasonably Well

Returns on Capital Paint A Bright Future For Dalian BIO-CHEM (SHSE:603360)

Apr 23
Returns on Capital Paint A Bright Future For Dalian BIO-CHEM (SHSE:603360)

Dalian BIO-CHEM Company Limited (SHSE:603360) Surges 41% Yet Its Low P/E Is No Reason For Excitement

Apr 01
Dalian BIO-CHEM Company Limited (SHSE:603360) Surges 41% Yet Its Low P/E Is No Reason For Excitement

Here's Why Dalian BIO-CHEM (SHSE:603360) Can Manage Its Debt Responsibly

Mar 08
Here's Why Dalian BIO-CHEM (SHSE:603360) Can Manage Its Debt Responsibly

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Dalian BIO-CHEM jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

SHSE:603360 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
9/30/20241,110300248304N/A
6/30/20241,076303175211N/A
3/31/20241,146354151223N/A
12/31/20231,066328322390N/A
9/30/20231,104349372433N/A
6/30/20231,169365460525N/A
3/31/20231,220377421478N/A
12/31/20221,257403346480N/A
9/30/20221,318426243400N/A
6/30/20221,19235541240N/A
3/31/20221,08229720211N/A
12/31/20211,006250-50142N/A
9/30/2021875203-69144N/A
6/30/202182721713207N/A
3/31/2021768184-11178N/A
12/31/2020750222101211N/A
9/30/2020837251195268N/A
6/30/2020920322201254N/A
3/31/2020934365243293N/A
12/31/2019872307177240N/A
9/30/201972727171155N/A
6/30/201962619547145N/A
3/31/201953915039136N/A
12/31/201852814547135N/A
9/30/201851712760130N/A
6/30/2018471109N/A93N/A
3/31/2018440100N/A79N/A
12/31/2017410100N/A76N/A
9/30/2017392107N/A115N/A
6/30/2017393109N/A132N/A
3/31/2017402107N/A125N/A
12/31/201638998N/A120N/A
9/30/201636582N/A99N/A
12/31/201532857N/A74N/A
12/31/201434764N/A60N/A
12/31/201329149N/A54N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 603360's forecast earnings growth is above the savings rate (2.9%).

Ertrag vs. Markt: Insufficient data to determine if 603360's earnings are forecast to grow faster than the CN market

Hohe Wachstumserträge: Insufficient data to determine if 603360's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if 603360's revenue is forecast to grow faster than the CN market.

Hohe Wachstumseinnahmen: Insufficient data to determine if 603360's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 603360's Return on Equity is forecast to be high in 3 years time

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y